AbbVie announces positive data from phase III ADVANCE trial for CGRP receptor antagonist atogepant in migraine prevention

Study (n=910) reports patients treated in 10 mg/30 mg/60 mg atogepant arms experienced decrease of 3.69/3.86/4.2 days, respectively, in mean monthly migraine days, compared to patients in placebo arm, who experienced a decrease of 2.48 days (all dose groups vs. placebo, p<0.0001)

Biospace Inc.